WO2012068998A3 - 一种曲安奈德眼用制剂及其制备方法 - Google Patents

一种曲安奈德眼用制剂及其制备方法 Download PDF

Info

Publication number
WO2012068998A3
WO2012068998A3 PCT/CN2011/082829 CN2011082829W WO2012068998A3 WO 2012068998 A3 WO2012068998 A3 WO 2012068998A3 CN 2011082829 W CN2011082829 W CN 2011082829W WO 2012068998 A3 WO2012068998 A3 WO 2012068998A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
purified water
sterile purified
solution
triamcinolone acetonide
Prior art date
Application number
PCT/CN2011/082829
Other languages
English (en)
French (fr)
Other versions
WO2012068998A2 (zh
Inventor
吴智南
陈小坚
梁福尧
Original Assignee
金健亚洲集团有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 金健亚洲集团有限公司 filed Critical 金健亚洲集团有限公司
Publication of WO2012068998A2 publication Critical patent/WO2012068998A2/zh
Publication of WO2012068998A3 publication Critical patent/WO2012068998A3/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/CN2011/082829 2010-11-24 2011-11-24 一种曲安奈德眼用制剂及其制备方法 WO2012068998A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201010557241.8 2010-11-24
CN201010557241A CN102008488B (zh) 2010-11-24 2010-11-24 一种曲安奈德眼用制剂及其制备方法

Publications (2)

Publication Number Publication Date
WO2012068998A2 WO2012068998A2 (zh) 2012-05-31
WO2012068998A3 true WO2012068998A3 (zh) 2012-07-19

Family

ID=43838953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/082829 WO2012068998A2 (zh) 2010-11-24 2011-11-24 一种曲安奈德眼用制剂及其制备方法

Country Status (2)

Country Link
CN (1) CN102008488B (zh)
WO (1) WO2012068998A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
CN103110686B (zh) * 2013-02-04 2016-03-23 广州花海药业股份有限公司 一种治疗糖尿病性视网膜病变的药物及其制备方法
CN104055728B (zh) * 2014-06-16 2016-10-12 温州医科大学 一种曲安奈德水凝胶眼用制剂的制备方法
CN118021719A (zh) * 2022-11-11 2024-05-14 北京华视诺维医疗科技有限公司 一种曲安奈德组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1288372A (zh) * 1998-01-22 2001-03-21 参天制药株式会社 氟米龙眼用混悬液
CN1562030A (zh) * 2004-04-20 2005-01-12 沈阳药科大学 以hpmc为基质的加替沙星眼用凝胶剂及其制备方法
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
US20090233890A1 (en) * 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
CN102008488A (zh) * 2010-11-24 2011-04-13 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN101450036A (zh) * 2006-12-26 2009-06-10 济南康泉医药科技有限公司 一种同载糖皮质激素和化疗药物的抗癌缓释剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1288372A (zh) * 1998-01-22 2001-03-21 参天制药株式会社 氟米龙眼用混悬液
CN1562030A (zh) * 2004-04-20 2005-01-12 沈阳药科大学 以hpmc为基质的加替沙星眼用凝胶剂及其制备方法
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
US20090233890A1 (en) * 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
CN102008488A (zh) * 2010-11-24 2011-04-13 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法

Also Published As

Publication number Publication date
WO2012068998A2 (zh) 2012-05-31
CN102008488B (zh) 2012-10-10
CN102008488A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
MX2012003296A (es) Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.
NZ606578A (en) Method for suspending particles in alcoholic liquid composition and corresponding liquid composition
MX2013014846A (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
WO2009125297A3 (es) Método para la producción de la composición de ácido hipocloroso y aplicaciones
AU2013334740A8 (en) Stable, low viscosity antibody formulation
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
WO2007005633A3 (en) Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2012068998A3 (zh) 一种曲安奈德眼用制剂及其制备方法
HRP20220626T1 (hr) Otopine bimatoprosta i timolola bez konzervansa
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
WO2009063962A1 (ja) 薬物含有脂肪乳剤およびその製造方法
MX342842B (es) Composiciones que tienen concentraciones incrementadas de carboximetilcelulosa.
MX356892B (es) Composiciones nutricionales liquidas, claras estables en anaquel que comprenden galato de epigalocatequina (egcg) y metodos para prepararlas.
MY178249A (en) Solid dialysis a agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
JP2013518051A5 (zh)
MX2019000031A (es) Procedimientos para la preparación de una solución de levotiroxina.
PH12016500572A1 (en) Solid dialysis a agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same
CN104940039B (zh) 复方酮康唑发用洗剂
RU2018119685A (ru) Жидкий концентрат напитка с растворимыми волокнами и способ доставки растворимого волокна
WO2011063775A3 (en) Pectin complexes of sartans and pharmaceutical compositions based thereon
RU2013147613A (ru) Местное дезинфицирующее средство, содержащее йод, обладающее низким содержанием поверхностно-активного вещества
CN106474131A (zh) 一种复合维生素颗粒剂及其制备方法
BR112014013564A8 (pt) composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz
CN104721198A (zh) 一种含雌二醇、土霉素悬浮剂及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11843015

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11843015

Country of ref document: EP

Kind code of ref document: A2